Business

InVentiv drops IPO, takes equity investment from Advent

Four months after it registered for an initial public offering, inVentiv Health Inc. said Monday that it has withdrawn its plan to go public and accepted an unspecified financial investment from private equity firm Advent International Corp.

Burlington-based inVentiv, which manages clinical trials for drug makers and helps them commercialize medicines, is now owned equally by Advent and Boston private equity firm Thomas H. Lee Partners, which paid more than $1 billion to buy the company in 2010, the company said.

Advertisement

InVentiv said the investment from Advent will boost its value to $3.8 billion. The private company said it earned $343 million on sales of $2.2 billion last year and has helped develop or commercialize 80 percent of the drugs approved by the Food and Drug Administration and 70 percent approved by European regulators during the past five years.

In its IPO registration, inVentiv had said it would seek to raise up to $100 million. The company, which has acquired many smaller contract research organizations in recent years, said it has about 14,000 employees around the world.

Robert Weisman can be reached at robert.weisman@globe.com. Follow him on Twitter @GlobeRobW.

Correction: An earlier version of this story misstated Thomas H. Lee Partners’ investment history with the company.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.